- Home
- GRCE vs CGTX Comparison
GRCE vs CGTX Comparison
Compare GRCE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- CGTX
- Stock Information
- Founded
- GRCE 2002
- CGTX 2007
- Country
- GRCE United States
- CGTX United States
- Employees
- GRCE N/A
- CGTX N/A
- Industry
- GRCE
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GRCE
- CGTX Health Care
- Exchange
- GRCE NYSE
- CGTX Nasdaq
- Market Cap
- GRCE 32.1M
- CGTX 26.8M
- IPO Year
- GRCE N/A
- CGTX 2021
- Fundamental
- Price
- GRCE $2.31
- CGTX $0.41
- Analyst Decision
- GRCE Strong Buy
- CGTX Strong Buy
- Analyst Count
- GRCE 1
- CGTX 6
- Target Price
- GRCE $12.00
- CGTX $7.50
- AVG Volume (30 Days)
- GRCE 27.2K
- CGTX 659.3K
- Earning Date
- GRCE 05-15-2025
- CGTX 03-20-2025
- Dividend Yield
- GRCE N/A
- CGTX N/A
- EPS Growth
- GRCE N/A
- CGTX N/A
- EPS
- GRCE N/A
- CGTX N/A
- Revenue
- GRCE N/A
- CGTX N/A
- Revenue This Year
- GRCE N/A
- CGTX N/A
- Revenue Next Year
- GRCE N/A
- CGTX N/A
- P/E Ratio
- GRCE N/A
- CGTX N/A
- Revenue Growth
- GRCE N/A
- CGTX N/A
- 52 Week Low
- GRCE $2.07
- CGTX $0.34
- 52 Week High
- GRCE $4.97
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- CGTX 40.25
- Support Level
- GRCE N/A
- CGTX $0.41
- Resistance Level
- GRCE N/A
- CGTX $0.44
- Average True Range (ATR)
- GRCE 0.00
- CGTX 0.04
- MACD
- GRCE 0.00
- CGTX 0.00
- Stochastic Oscillator
- GRCE 0.00
- CGTX 27.42
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.